Search research articles
Contact Us
Filters
Showing results (11-20 of 239) with videos related to
Page
of 24
Sort By:
Journal of Market Access & Health Policy
|
March 8, 2017
Value added medicines: what value repurposed medicines might bring to society?
Mondher Toumi, Cécile Rémuzat
Applied Health Economics and Health Policy
|
June 21, 2011
Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence
Szymon Jarosławski, Mondher Toumi
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
September 26, 2015
Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention
Szymon Jarosławski, Mondher Toumi
Przeglad Epidemiologiczny
|
May 4, 2016
Comparison of economic and health implications from earlier detection of HIV infection in the United Kingdom and Poland
Vladimir Zah, Mondher Toumi
Journal of Market Access & Health Policy
|
November 28, 2018
Non-profit drug research and development: the case study of Genethon
Szymon Jarosławski, Mondher Toumi
Expert Review of Pharmacoeconomics & Outcomes Research
|
January 28, 2012
Access to orphan drugs in Europe: current and future issues
Morgane Michel, Mondher Toumi
BMC Health Services Research
|
October 11, 2011
Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
Szymon Jarosławski, Mondher Toumi
Journal of Market Access & Health Policy
|
June 4, 2019
Measuring the health-related quality of life in young children: how far have we come?
Nicola Germain, Samuel Aballéa, Mondher Toumi
Vaccine
|
September 14, 2010
Comment on the contribution by Weycker et al., "Cost of routine immunization of young children against rotavirus infection with Rotarix ® versus RotaTeq ®"
Mondher Toumi, Timo Vesikari, Carlo Giaquinto
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 11, 2006
Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?
Karina Hansen, Christophe Lançon, Mondher Toumi
Page
of 24
Search research articles
Search
Showing results (11-20 of 239) with videos related to
Sort By:
Page
of 24
Journal of Market Access & Health Policy
|
March 8, 2017
Value added medicines: what value repurposed medicines might bring to society?
Mondher Toumi, Cécile Rémuzat
Applied Health Economics and Health Policy
|
June 21, 2011
Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence
Szymon Jarosławski, Mondher Toumi
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
September 26, 2015
Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention
Szymon Jarosławski, Mondher Toumi
Przeglad Epidemiologiczny
|
May 4, 2016
Comparison of economic and health implications from earlier detection of HIV infection in the United Kingdom and Poland
Vladimir Zah, Mondher Toumi
Journal of Market Access & Health Policy
|
November 28, 2018
Non-profit drug research and development: the case study of Genethon
Szymon Jarosławski, Mondher Toumi
Expert Review of Pharmacoeconomics & Outcomes Research
|
January 28, 2012
Access to orphan drugs in Europe: current and future issues
Morgane Michel, Mondher Toumi
BMC Health Services Research
|
October 11, 2011
Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
Szymon Jarosławski, Mondher Toumi
Journal of Market Access & Health Policy
|
June 4, 2019
Measuring the health-related quality of life in young children: how far have we come?
Nicola Germain, Samuel Aballéa, Mondher Toumi
Vaccine
|
September 14, 2010
Comment on the contribution by Weycker et al., "Cost of routine immunization of young children against rotavirus infection with Rotarix ® versus RotaTeq ®"
Mondher Toumi, Timo Vesikari, Carlo Giaquinto
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
March 11, 2006
Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?
Karina Hansen, Christophe Lançon, Mondher Toumi
Page
of 24